ESMO Asia 2016 Congress

Oncology Meeting Resources

16 Dec - 19 Dec, Singapore

ESMO Asia 2016 Square

The ESMO Asia Congress comprised both scientific and educational tracks prepared by an international scientific committee. There was a strong emphasis on state of the art science, including a call for abstracts, and the current standard of care across all major tumour types.

Abstracts, presentations and webcasts from the ESMO Asia 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
Axel Hillmer Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making Advances in precision medicine of gastric cancer
Ian Chau Can we be more precise – given the various standards - in peri-operative treatment for gastroesophageal cancer? Advances in precision medicine of gastric cancer
Florian Lordick Innovative treatment in advanced gastric and gastroesophageal cancer: More precise, more efficacious and safer? Advances in precision medicine of gastric cancer
Ravindran Kanesvaran Introduction Immunotherapy will be first line management for everything within 10 years
Ian Davis Prostate cancer Immunotherapy will be first line management for everything within 10 years
Joaquim Bellmunt Bladder cancer Immunotherapy will be first line management for everything within 10 years
Daniel Y.C. Heng Renal cancer Immunotherapy will be first line management for everything within 10 years
Ruby Huang 297O - Stratifying ovarian cancer based on AXL signaling for therapeutic targeting Gynaecological cancers
Jing Tan Biomarkers Immunotherapy will be first line management for everything within 10 years
Diar Aziz 298O - The clinical significance of deregulated cyclin E1 in high grade serous ovarian cancer (HGSOC) Gynaecological cancers
Ian Davis Conclusions and clinical perspectives Immunotherapy will be first line management for everything within 10 years
Li-jun Di 299O - Genomic Signature identifying origins of EOC from Fallopian tube and ovary epithelium Gynaecological cancers
Cristiana Sessa Invited Discussant 297O, 298O and 299O Gynaecological cancers
Rema Gvamichava 300O - Assessment of the effectiveness of cervical cancer screening Gynaecological cancers
Nabiha Islam 301O - Exploring perceptions of cervical cancer in Dhaka, Bangladesh Gynaecological cancers